.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Merck
Fish and Richardson
Cipla
UBS
QuintilesIMS
Colorcon
Teva
AstraZeneca

Generated: December 17, 2017

DrugPatentWatch Database Preview

Pharmacyclics Inc Company Profile

« Back to Dashboard

What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?

PHARMACYCLICS INC has one approved drug.

There are twenty-one US patents protecting PHARMACYCLICS INC drugs.

There are one hundred and eighty-seven patent family members on PHARMACYCLICS INC drugs in thirty-eight countries and twenty-two supplementary protection certificates in ten countries.

Summary for Pharmacyclics Inc

International Patents:187
US Patents:21
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
Pharmacyclics IncIMBRUVICAibrutinibCAPSULE;ORAL205552-001Nov 13, 2013RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Pharmacyclics Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,809,273Inhibitors of Bruton's tyrosine kinase► Subscribe
8,748,439Inhibitors of Bruton's tyrosine kinase► Subscribe
8,236,812Inhibitors of bruton's tyrosine kinase► Subscribe
8,940,750Inhibitors of bruton's tyrosine kinase► Subscribe
9,556,182Inhibitors of Bruton's tyrosine kinase► Subscribe
8,741,908Inhibitors of bruton's tyrosine kinase► Subscribe
9,409,911Inhibitors of bruton's tyrosine kinase► Subscribe
9,266,893Inhibitors of Bruton's tyrosine kinase► Subscribe
8,658,653Inhibitors of Bruton's tyrosine kinase► Subscribe
7,732,454Inhibitors of Bruton's tyrosine kinase► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pharmacyclics Inc Drugs

Country Document Number Estimated Expiration
Slovenia2526934► Subscribe
Israel239156► Subscribe
New Zealand604040► Subscribe
Singapore11201408067Y► Subscribe
Eurasian Patent Organization201000599► Subscribe
Spain2585902► Subscribe
Portugal2526771► Subscribe
HungaryS1500018► Subscribe
Eurasian Patent Organization024255► Subscribe
Spain2617150► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pharmacyclics Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000027Germany► SubscribePRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20141021
2017000015Germany► SubscribePRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703
0728Netherlands► SubscribeDETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN
3 5006-2015Slovakia► SubscribePRODUCT NAME: IBRUTINIB; REGISTRATION NO/DATE: EU/1/14/945 20141023
692Luxembourg► SubscribePRODUCT NAME: IBRUTINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI. FIRST REGISTRATION: 20141023
321Luxembourg► SubscribePRODUCT NAME: INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
2016000093Germany► SubscribePRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
90021-0Sweden► SubscribePRODUCT NAME: IBRUTINIB ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/14/945 20141023
C0029France► SubscribePRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
2015 00021Denmark► SubscribePRODUCT NAME: IBRUTINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 20141021
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
US Department of Justice
Cantor Fitzgerald
Queensland Health
Johnson and Johnson
Accenture
Deloitte
Baxter
Dow
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot